KBC Private Partners Life Sciences
The computed 12-month bankruptcy probability of KBC Private Partners Life Sciences is 1.2% (low). The 2024 annual accounts show equity of €24.89M and a net result of €1.41M. Equity is growing by ~16.4% per year across the filed fiscal years. The company has been active since 2021 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €24.89M |
| Net result | €1.41M |
| Active | 5 yrs |
| Locations | 1 |
Exceptional profile, strong across almost every axis.
All 5 axes are computed from data Checked has read.
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
The full score breakdown, per-year score history and the indicative credit limit are in Kantoor S.
See plans →How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
Show 9 other metrics
| Fiscal year | 2024 |
|---|---|
| Deposit | verkort |
| Revenue | - |
| EBITDA | €-460k |
| Net profit | €1.41M |
| Cash flow | €1.58M |
| Staff costs | - |
| Income taxes | €29k |
| Dividends | - |
| Total assets | €24.92M |
| Equity | €24.89M |
| Debt | €31k |
| of which ≤ 1y | €31k |
| of which > 1y | - |
| Working capital | €2.76M |
| Employees (FTE) | 0.0 |
| 2024 | |
|---|---|
| Current ratio | 89.36 |
| Quick ratio | 89.36 |
| Working capital ratio | 11.1% |
| Solvency | 99.9% |
| Debt / equity | 0.00 |
| Long-term debt ratio | - |
| Interest coverage | -30.21 |
| Gross margin | - |
| Net margin | - |
| ROA | 5.6% |
| ROE | 5.6% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
Full annual accounts (22 line items)
| Line item | Code | 2024 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €24.92M |
| Fixed assets | 21/28 | €21.81M |
| Formation expenses | 20 | €320k |
| Financial fixed assets | 28 | €21.81M |
| Current assets | 29/58 | €2.79M |
| Amounts receivable within one year | 40/41 | €117k |
| Cash & bank | 54/58 | €2.67M |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €24.92M |
| Equity | 10/15 | €24.89M |
| Contributions / capital | 10/11 | €24.05M |
| Accumulated profits (losses) | 14 | €837k |
| Amounts payable | 17/49 | €31k |
| Amounts payable within one year | 42/48 | €31k |
| Trade debts payable within one year | 44 | €31k |
| Income statement | ||
| Gross operating margin | 9900 | €-459k |
| Operating result | 9901 | €-636k |
| Financial income | 75 | €2.11M |
| Financial charges | 65 | €15k |
| Result before taxes | 9903 | €1.43M |
| Income taxes | 67/77 | €29k |
| Net result for the period | 9904 | €1.41M |
| Result to be appropriated | 9905 | €1.41M |
| NACE primary | - |
| Legal form | Limited partnership(612) |
| Incorporation | 02-06-2021 |
| Status | Active |
| Postal code | 1080 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 21012A0177/00B004 | Brussels | 1.6 ha | 1 · 1.3 ha | 51.3 m · 7 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
Of the 8 Belgian State Gazette acts we know for this company, 1 has been read. The other 7 have not been read yet: what they contain is neither established nor disproved here.
03-08-2026 Act object · Board meeting · Capital decrease · Capital
- Act object: Statutenwijziging - kapitaalvermindering · KBC Private Partners Life Sciences
- Publication: 03/08/2026 · KBC Private Partners Life Sciences
- Filing: 27/07/2026 · KBC Private Partners Life Sciences
- Board meeting: 13/07/2026 · KBC Private Partners Life Sciences
- Capital decrease: after: 42.076.941,06 EUR, delta: 8.746.815,92 EUR, amount: 42076941.06, before: 50.823.756,98 EUR, method: terugbetaling in speciën aan de vennoten ... zonder vernietiging van aandelen, currency: EUR · KBC Private Partners Life Sciences
- Capital: amount: 42076941.06, shares: 58.611.111, currency: EUR · KBC Private Partners Life Sciences
- Statute amendment: Artikel 7 vervangen · KBC Private Partners Life Sciences
- Filing representative: bijzondere volmacht ... teneinde de vereiste bekendmakings- en neerleggingsformaliteiten ... te vervullen · Alix Stockman
- Filing representative: Bijzonder gevolmachtigde · Tom Van Berckelaer
Technical details
{
"facts": [
{
"type": "act_object",
"quote": "Onderwerp akte: Statutenwijziging - kapitaalvermindering",
"value": "Statutenwijziging - kapitaalvermindering",
"object": null,
"subject": "e1"
},
{
"date": "2026-08-03",
"type": "publication",
"quote": "Bijlagen bij het Belgisch Staatsblad - 03/08/2026",
"value": "03/08/2026",
"object": null,
"subject": "e1"
},
{
"date": "2026-07-27",
"type": "filing",
"quote": "neergelegd/ontvangen opd 27 JULI 2026",
"value": "27/07/2026",
"object": null,
"subject": "e1"
},
{
"date": "2026-07-13",
"type": "board_meeting",
"quote": "Uit de notulen van de zaakvoerder d.d. 13 juli 2026",
"value": "13/07/2026",
"object": null,
"subject": "e1"
},
{
"type": "capital_decrease",
"quote": "kapitaalvermindering werd doorgevoerd ten belope van 8.746.815,92 EUR ... kapitaal van de vennootschap gebracht van 50.823.756,98 EUR op 42.076.941,06 EUR",
"value": {
"after": "42.076.941,06 EUR",
"delta": "8.746.815,92 EUR",
"amount": 42076941.06,
"before": "50.823.756,98 EUR",
"method": "terugbetaling in speci\u00EBn aan de vennoten ... zonder vernietiging van aandelen",
"currency": "EUR"
},
"amount": 8746815.92,
"object": null,
"subject": "e1",
"currency": "EUR",
"_value_raw": {
"after": "42.076.941,06 EUR",
"delta": "8.746.815,92 EUR",
"before": "50.823.756,98 EUR",
"method": "terugbetaling in speci\u00EBn aan de vennoten ... zonder vernietiging van aandelen"
}
},
{
"type": "capital",
"quote": "Er werden inbrengen gedaan in het Fonds ten belope van twee\u00EBnveertig miljoen zesenzeventig duizend negenhonderd eenenveertig euro en zes cent (42.076.941,06 EUR). Als vergoeding voor de inbrengen werden achtenvijftig miljoen zeshonderd en elf duizend honderd en elf (58.611.111) aandelen zonder vermelding van nominale waarde uitgegeven, waarvan achtenvijftig miljoen zeshonderd en een duizend honderd en elf (58.601.111) van soort A en tienduizend (10.000) aandelen van soort B.",
"value": {
"amount": 42076941.06,
"shares": "58.611.111",
"currency": "EUR",
"share_types": [
{
"type": "A",
"count": "58.601.111"
},
{
"type": "B",
"count": "10.000"
}
]
},
"amount": 42076941.06,
"object": null,
"subject": "e1",
"currency": "EUR",
"_value_raw": {
"amount": "42.076.941,06 EUR",
"shares": "58.611.111",
"share_types": [
{
"type": "A",
"count": "58.601.111"
},
{
"type": "B",
"count": "10.000"
}
]
}
},
{
"type": "statute_amendment",
"quote": "beslist de zaakvoerder ... de tekst van artikel 7 van de statuten te vervangen",
"value": "Artikel 7 vervangen",
"object": null,
"subject": "e1"
},
{
"type": "filing_representative",
"quote": "Er werd een bijzondere volmacht verleend aan Alix Stockman en alle andere werknemers van Finvision ... teneinde de vereiste bekendmakings- en neerleggingsformaliteiten ... te vervullen",
"value": "bijzondere volmacht ... teneinde de vereiste bekendmakings- en neerleggingsformaliteiten ... te vervullen",
"object": "e1",
"subject": "e2"
},
{
"type": "filing_representative",
"quote": "Van Berckelaer Tom (voor Finvision Accountancy, Tax \u0026 Legal BV) Bijzonder gevolmachtigde",
"value": "Bijzonder gevolmachtigde",
"object": "e1",
"subject": "e4"
}
],
"act_meta": {
"outcome": "clean",
"model_id": 50,
"verified": true,
"extractor": "verified-v1",
"ocr_chars": 3278,
"truncated": false
},
"entities": [
{
"id": "e1",
"kbo": "0769.268.594",
"kind": "company",
"name": "KBC Private Partners Life Sciences",
"attrs": {
"seat": "Havenlaan 2, 1080 Sint-Jans-Molenbeek",
"legal_form": "Commanditaire vennootschap"
}
},
{
"id": "e2",
"kbo": null,
"kind": "person",
"name": "Alix Stockman",
"attrs": {}
},
{
"id": "e3",
"kbo": null,
"kind": "org",
"name": "Finvision",
"attrs": {}
},
{
"id": "e4",
"kbo": null,
"kind": "person",
"name": "Tom Van Berckelaer",
"attrs": {}
},
{
"id": "e5",
"kbo": null,
"kind": "company",
"name": "Finvision Accountancy, Tax \u0026 Legal BV",
"attrs": {}
}
]
}02-03-2026 Capital decrease of €2,536,199 to €50,823,756.98
- €53.359.955,98 → €50.823.756,98
Technical details
{
"events": [
{
"kind": "capital_decrease",
"after_eur": 50823756.98,
"delta_eur": -2536199.0,
"before_eur": 53359955.98,
"share_emission": {
"agio_eur": null,
"share_form": "unknown",
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": "distribution_to_shareholders",
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": 2536199.0,
"statutory_unavailable_equity_op": null
}
],
"notary": {
"name": null,
"firm_city": null,
"firm_name": null,
"office_city": "Luik",
"is_associated": false
},
"act_meta": {
"language": "nl",
"pub_date": "2026-03-02",
"filing_date": "2026-02-23",
"act_kind_objet": "Onderwerp akte:"
},
"decision": {
"body": "eenige_bestuurder_schriftelijk",
"act_date": "2026-02-23",
"unanimous": null,
"under_authorized_capital": true,
"underlying_resolution_date": "2025-12-18"
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0769.268.594",
"name_full": "KBC Private Partners Life Sciences",
"legal_form": "Commanditaire vennootschap",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": "org",
"org_kbo": null,
"org_name": "Finvision Accountancy bv",
"person_name": "Tom Van Berckelaer",
"org_rep_person_name": "Tom Van Berckelaer",
"person_role_at_subject": null
},
"co_filed_documents": [
"Eensluidend afschrift notulen van de zaakvoerder",
"Eensluidend afschrift van de geco\u00F6rdineerde statuten"
],
"shareholders_after": [],
"share_classes_after": [
{
"n_shares": 58601111,
"class_name": "A",
"capital_share_eur": null,
"voting_rights_per_share": null
},
{
"n_shares": 10000,
"class_name": "B",
"capital_share_eur": null,
"voting_rights_per_share": null
}
]
}20-08-2025 Mazars Bedrijfsrevisoren bv reappointed as statutory auditor
- Mazars Bedrijfsrevisoren bv, Commissaris
Technical details
{
"events": [
{
"kind": "commissaris_renew",
"role": "commissaris",
"person": {
"rrn": null,
"name": "Mazars Bedrijfsrevisoren bv",
"address": null,
"birth_date": null
},
"evidence_quote": "Uit de notulen van de algemene vergadering van 03/06/2025 blijkt de herbenoeming van Mazars Bedrijfsrevisoren bv (0428.837.889), met zetel te 1210 Sint-Joost-ten-Node, Bolwerklaan 21/8 als commissaris van de vennootschap."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0769.268.594",
"name_full": "KBC PRIVATE PARTNERS LIFE SCIENCES",
"legal_form": "CommV"
}
}20-11-2024 Capital decrease of €2,721,130 to €53,359,955.98
- €56.081.085,98 → €53.359.955,98
Technical details
{
"events": [
{
"kind": "capital_decrease",
"amount": 2721130.0,
"currency": "EUR",
"after_eur": 53359955.98,
"delta_eur": -2721130.0,
"before_eur": 56081085.98,
"amount_type": "kapitaal_effectief",
"effective_date": "2024-09-30",
"evidence_quote": "Vit de notulen van de zaakvoerder d.d. 30/09/2024 blijkt dat er een kapitaalvermindering werd doorgevoerd ten belope van 2.721.130,00 EUR... Als gevolg van de kapitaalvermindering werd het kapitaal van de vennootschap gebracht van 56.081.085,98 euro op 53.359.955,98 euro",
"contribution_type": "cash"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0769.268.594",
"name_full": "KBC PRIVATE PARTNERS LIFE SCIENCES",
"legal_form": "CommV"
}
}27-06-2024 Capital decrease of €2,530,025.02 to €56,081,085.98
- €58.611.111 → €56.081.085,98
Technical details
{
"events": [
{
"kind": "capital_decrease",
"amount": 2530025.02,
"currency": "EUR",
"after_eur": 56081085.98,
"delta_eur": -2530025.02,
"before_eur": 58611111.0,
"amount_type": "kapitaal_effectief",
"effective_date": "2024-02-20",
"evidence_quote": "Uit de notulen van de zaakvoerder d.d. 20 februari 2024 blijkt dat er een kapitaalvermindering werd doorgevoerd ten belope van 2.530.025,02 EUR, door terugbetaling in speci\u00EBn aan de vennoten van een bedrag gelijk aan het bedrag van de kapitaalvermindering en zonder vernietiging van aandelen. Als gevolg van de kapitaalvermindering werd het kapitaal van de vennootschap gebracht van 58.611.111,00 euro op 56.081.085,98 euro",
"contribution_type": "cash"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0769.268.594",
"name_full": "KBC PRIVATE PARTNERS LIFE SCIENCES",
"legal_form": "CommV"
}
}16-11-2021 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"statute_change": {
"name_change": false,
"seat_change": false,
"object_change": false,
"effective_date": "2021-10-27",
"legal_form_change": false
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0769.268.594",
"name_full": "KBC PRIVATE PARTNERS LIFE SCIENCES",
"legal_form": "CommV"
},
"signature_regime": null,
"special_mandates": [],
"governance_change": {
"admin_delegated_added": []
}
}15-10-2021 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"statute_change": {
"name_change": false,
"seat_change": false,
"object_change": false,
"effective_date": "2021-09-15",
"legal_form_change": false
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0769.268.594",
"name_full": "KBC PRIVATE PARTNERS LIFE SCIENCES",
"legal_form": "CommV"
},
"signature_regime": null,
"special_mandates": [],
"governance_change": {
"admin_delegated_added": []
}
}04-06-2021 Incorporation of a new CommV
Technical details
{
"kind": "oprichting",
"seat": "1080 Sint-Jans-Molenbeek, Havenlaan 2",
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"founders": [
{
"org": {
"kbo": null,
"name": "KBC Securities"
},
"kind": "rechtspersoon",
"person": null,
"share_class": "A",
"partner_role": null,
"holder_org_kbo": null,
"holder_org_name": "KBC Securities",
"contribution_type": "cash",
"amount_paid_in_eur": 0,
"holder_person_name": null,
"is_subscriber_only": false,
"n_shares_subscribed": 1000,
"amount_subscribed_eur": 1000,
"is_anonymous_silent_partner": false
},
{
"org": {
"kbo": null,
"name": "KBC Bank"
},
"kind": "rechtspersoon",
"person": null,
"share_class": "B",
"partner_role": null,
"holder_org_kbo": null,
"holder_org_name": "KBC Bank",
"contribution_type": "cash",
"amount_paid_in_eur": 0,
"holder_person_name": null,
"is_subscriber_only": true,
"n_shares_subscribed": 10000,
"amount_subscribed_eur": 10000,
"is_anonymous_silent_partner": false
}
],
"capital_eur": 11000,
"subject_company": {
"kbo": "0769.268.594",
"name_full": "KBC Private Partners Life Sciences",
"legal_form": "CommV"
},
"initial_directors": [],
"incorporation_date": "2021-06-01",
"post_incorporation_mandates": []
}| Legal nameNL | KBC Private Partners Life Sciences |